Hossein Borghaei, DO, MS
The emergence of chemoimmunotherapy combinations in the stage IV nonsquamous non–small cell lung cancer (NSCLC) paradigm has resulted in clear survival gains for patients, regardless of PD-L1 expression, said Hossein Borghaei, DO, MS.
Future research, he added, will focus on optimal approaches for patients who progress on these frontline regimens and identifying biomarkers of response.
“Several [chemoimmunotherapy] trials have had a huge impact on how we treat this disease and many of them have changed standard of care for our patients,” said Borghaei, a professor and chief of thoracic oncology at Fox Chase Cancer Center.
... to read the full story